✦ LIBER ✦

A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061

✍ Scribed by John F Deeken; Michelle A Rudek; Page C Moore; David Aboulafia; Ryan Sullivan; John Gerecitano; Mary Cianfrocca; David Henry; Lee Ratner; Bruce Dezube; Kimberly Mosby; Melinda Tibbals; Richard F Little; S P Ivy; Ronald T Mitsuyasu

Book ID: 115023340
Publisher: BioMed Central
Year: 2012
Tongue: English
Weight: 83 KB
Volume: 7
Category: Article
ISSN: 1750-9378
DOI: 10.1186/1750-9378-7-s1-o15

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cancer survival in patients with HIV/AID

Cancer survival in patients with HIV/AIDS in the era of highly active antiretroviral therapy in Taiwan: A population-based cohort study

✍ Lin, Chih-Shin; Lin, Charlene; Weng, Shih-Feng; Lin, Shih-Wei; Lin, Yung-Song 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 420 KB

[715] EVALUATION OF LIVER DAMAGE IN HIV-

[715] EVALUATION OF LIVER DAMAGE IN HIV-1 -POSITIVE PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) WITH CHRONIC TRANSAMINASES ELEVATION OF UNKNOWN ORIGIN (THE HEALTH STUDY)

✍ P. Ingiliz; M.A. Valantin; C. Duvivier; A. Simon; S. Dominguez; R. Tubiana; K. F 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 275 KB

A pilot study of the safety and efficacy

A pilot study of the safety and efficacy of thymosin α1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy

✍ D. CHADWICK; J. PIDO-LOPEZ; A. PIRES; N. IMAMI; F. GOTCH; J. S. VILLACIAN; S. RA 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

601 A First-in-human, Phase 1 Clinical S

601 A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors

✍ Mahalingam, D.; Wilding, G.; Denmeade, S.; Sarantopoulas, J.; Cosgrove, D.; Cetn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 79 KB

607 POSTER Impressive anti-tumor activit

607 POSTER Impressive anti-tumor activity of combined erbB1 and erbB2 blockade: a phase I and pharmacokinetics (PK) study of OSl-774 (Erlotinib; E) and Trastuzumab (T) in combination with weekly Paclitaxel (P) in patients (pts) with advanced solid tumors

✍ M. Beeram; J.S. De Bono; E.K. Rowinsky; P. O'Rourke; A. Ricart; L.A. Hammond; A. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 53 KB